| Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications DK Hiwase, V Saunders, D Hewett, A Frede, S Zrim, P Dang, L Eadie, ... Clinical Cancer Research 14 (12), 3881-3888, 2008 | 223 | 2008 |
| RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML AL Brown, P Arts, CL Carmichael, M Babic, J Dobbins, CE Chong, ... Blood advances 4 (6), 1131-1144, 2020 | 143 | 2020 |
| TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets DT Yeung, MP Osborn, DL White, S Branford, J Braley, A Herschtal, ... Blood, The Journal of the American Society of Hematology 125 (6), 915-923, 2015 | 116 | 2015 |
| Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells E Nievergall, HS Ramshaw, ASM Yong, M Biondo, SJ Busfield, G Vairo, ... Blood, The Journal of the American Society of Hematology 123 (8), 1218-1228, 2014 | 111 | 2014 |
| Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell … DK Hiwase, S Hiwase, M Bailey, G Bollard, AP Schwarer Biology of Blood and Marrow Transplantation 14 (1), 116-124, 2008 | 111 | 2008 |
| Myeloid neoplasms with germline DDX41 mutation JJC Cheah, CN Hahn, DK Hiwase, HS Scott, AL Brown International journal of hematology 106, 163-174, 2017 | 101 | 2017 |
| Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML S de Botton, P Fenaux, K Yee, C Récher, AH Wei, P Montesinos, ... Blood advances 7 (13), 3117-3127, 2023 | 86 | 2023 |
| Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome D Singhal, MM Kutyna, R Chhetri, LYA Wee, S Hague, L Nath, SV Nath, ... Haematologica 102 (12), 2021, 2017 | 75 | 2017 |
| Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple … DK Hiwase, G Bollard, S Hiwase, M Bailey, J Muirhead, AP Schwarer Cytotherapy 9 (6), 539-547, 2007 | 75 | 2007 |
| Loss of caspase-2 augments lymphomagenesis and enhances genomic instability in Atm-deficient mice J Puccini, S Shalini, AK Voss, M Gatei, CH Wilson, DK Hiwase, MF Lavin, ... Proceedings of the National Academy of Sciences 110 (49), 19920-19925, 2013 | 71 | 2013 |
| Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia N Shanmuganathan, IS Pagani, DM Ross, S Park, ASM Yong, JA Braley, ... Blood, The Journal of the American Society of Hematology 137 (9), 1196-1207, 2021 | 67 | 2021 |
| TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy E Nievergall, J Reynolds, CH Kok, DB Watkins, M Biondo, SJ Busfield, ... Leukemia 30 (6), 1263-1272, 2016 | 66 | 2016 |
| Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors DK Hiwase, DL White, JA Powell, VA Saunders, SA Zrim, AK Frede, ... Leukemia 24 (4), 771-778, 2010 | 63 | 2010 |
| Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy CN Hahn, P Venugopal, HS Scott, DK Hiwase Immunological reviews 263 (1), 257-278, 2015 | 56 | 2015 |
| The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution D Singhal, LYA Wee, MM Kutyna, R Chhetri, J Geoghegan, AW Schreiber, ... Leukemia 33 (12), 2842-2853, 2019 | 50 | 2019 |
| Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia L Schafranek, E Nievergall, JA Powell, DK Hiwase, T Leclercq, ... Leukemia 29 (1), 76-85, 2015 | 50 | 2015 |
| Ndfip1-deficient mice have impaired DMT1 regulation and iron homeostasis NJ Foot, YA Leong, LE Dorstyn, HE Dalton, K Ho, L Zhao, MD Garrick, ... Blood, The Journal of the American Society of Hematology 117 (2), 638-646, 2011 | 48 | 2011 |
| Dynamic assessment of RBC‐transfusion dependency improves the prognostic value of the revised‐IPSS in MDS patients DK Hiwase, D Singhal, C Strupp, R Chhetri, MM Kutyna, LA Wee, ... American journal of hematology 92 (6), 508-514, 2017 | 46 | 2017 |
| Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer D Singhal, CN Hahn, S Feurstein, LYA Wee, L Moma, MM Kutyna, ... Leukemia 35 (11), 3245-3256, 2021 | 45 | 2021 |
| Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies U Germing, EN Oliva, D Hiwase, A Almeida Hemasphere 3 (6), e314, 2019 | 41 | 2019 |
